e-learning
resources
Stockholm 2007
Monday 17.09.2007
Epidemiological and clinical aspects of tuberculosis control
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD)
B. Brashier, S. Gangavane, S. Valsa, S. N. Gaikwad, S. V. Ghorpade, S. Mandrekar, S. Salvi (Pune, Maharashtra, India)
Source:
Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Session:
Epidemiological and clinical aspects of tuberculosis control
Session type:
Thematic Poster Session
Number:
2585
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Brashier, S. Gangavane, S. Valsa, S. N. Gaikwad, S. V. Ghorpade, S. Mandrekar, S. Salvi (Pune, Maharashtra, India). Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD). Eur Respir J 2007; 30: Suppl. 51, 2585
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011
Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection?
Source: Eur Respir J 2001; 18: Suppl. 33, 172s
Year: 2001
Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity
Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)?
Year: 2018
The state of patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008
Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB)
Source: Eur Respir J 2006; 28: Suppl. 50, 395s
Year: 2006
Adenosine-related mechanisms in the COPD pathogenesis in pulmonary tuberculosis (PT) patients
Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair
Year: 2020
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 310s
Year: 2005
Microbiological features of the indicators of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) during remission
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Measurement of improved activities after pulmonary rehabilitation (PR) in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 223s
Year: 2001
The estimation of respiratory muscles (RM) status by echodensitometry in men with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2012 - Various issues in clinical physiology
Year: 2012
Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2006 - COPD therapy
Year: 2006
The relationship between fibroblasts and airway structure in patients with asthma and chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 148s
Year: 2001
The indices of body composition (IBC) in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - COPD diagnosis
Year: 2011
Predictive factors for the incidence of lung cancer (LC) complicated in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019
Large airways remodeling in chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2008 - Pathophysiology of respiratory diseases
Year: 2008
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Subpopulation structure of lymphocytes in patients with chronic obstructive pulmonary disease (COPD) during exacerbation and after treatment
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
Bronchiectasis impact outcomes in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept